Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Saturday, 04 / 20 / 2019

Articles

Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era

REVIEW ARTICLE

Use of Ribavirin for Hepatitis C Treatment in the Modern Direct-acting Antiviral Era

Poonam Mathur*, Shyamasundaran Kottilil and Eleanor Wilson

Division of Clinical Care and Research, Institute of Human Virology, University of Maryland School of Medicine, Baltimore, MD, USA

*Correspondence to: Poonam Mathur, Institute of Human Virology, University of Maryland School of Medicine, 725 W. Lombard St., Baltimore, MD 21201, USA. Tel: +1-443-326-0506, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2018;6(4):431-437 DOI: 10.14218/JCTH.2018.00007
Received: January 25, 2018 Accepted: June 24, 2018 Published online: September 27, 2018

Abstract

Ribavirin, once a staple of hepatitis C treatment, has significant drawbacks, including treatment-limiting side effects, the requirement for intensive laboratory monitoring, the need for frequent dose adjustments, and teratogenicity. These factors make it difficult to escalate ribavirin-based HCV treatment to most infected patients globally. Most studies have shown comparable response rates between ribavirin-inclusive and ribavirin-sparing regimens in uncomplicated patient populations. However, ribavirin is still used in the management of patients who have failed previous therapy as well as those with decompensated liver disease. In this review, we explore the evidence supporting the use of ribavirin in the current climate of hepatitis C treatment with oral combination direct-acting antiviral agents.

Keywords

Chronic hepatitis C, Direct-acting antivirals, Ribavirin

 

Journal of Clinical and Translational Hepatology 2018 vol. 6, 431-437  [ Html ] [ PDF Full-text ]

© The Authors 2018. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 logo

You are here: Home